menu
    • menu
    [{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-ADC","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TORL-2-307-MAB","moa":"B7-H3","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"European Network for Gynaecological Oncological Trial Groups","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase II","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TORL BioTherapeutics \/ European Network for Gynaecological Oncological Trial Groups","highestDevelopmentStatusID":"8","companyTruncated":"TORL BioTherapeutics \/ European Network for Gynaecological Oncological Trial Groups"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase II","graph3":"TORL BioTherapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Deep Track Capital","highestDevelopmentStatusID":"8","companyTruncated":"TORL BioTherapeutics \/ Deep Track Capital"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Series B Financing","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase II","graph3":"TORL BioTherapeutics","amount2":0.16,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"TORL BioTherapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TORL-3-600","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Translational Research In Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TORL-4-500","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"TORL BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TORL BioTherapeutics \/ Translational Research in Oncology","highestDevelopmentStatusID":"6","companyTruncated":"TORL BioTherapeutics \/ Translational Research in Oncology"},{"orgOrder":0,"company":"TORL BioTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Series C Financing","leadProduct":"TORL-1-23","moa":"CLDN-6","graph1":"Oncology","graph2":"Phase II","graph3":"TORL BioTherapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"TORL BioTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TORL BioTherapeutics \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by TORL BioTherapeutics

    Menu

    TORL BioTherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $96.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            TORL BioTherapeutics Secures $96M Series C Financing

                            Details : The Series C financing will support the development of TORL-1-23, an antibody-drug conjugate targeting CLDN-6, for Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer.

                            Product Name : TORL-1-23

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            October 07, 2025

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $96.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : European Network for Gynaecological Oncological Trial Groups

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

                            Details : TORL-1-23 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Ovarian Epithelial.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            November 15, 2024

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : European Network for Gynaecological Oncological Trial Groups

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Deep Track Capital

                            Deal Size : $158.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            TORL BioTherapeutics Secures $158 Million for Novel ADC Oncology Pipeline

                            Details : The financing will continue clinical development of TORL-1-23, a potentially best-in-class ADC for Claudin 6 positive tumors, through Phase 1 and pivotal Phase 2 trials.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            April 10, 2024

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Deep Track Capital

                            Deal Size : $158.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-4-500

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

                            Details : TORL-4-500 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 22, 2023

                            Lead Product(s) : TORL-4-500

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-3-600

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First in Human Study of TORL-3-600 in Participants With Advanced Cancer

                            Details : TORL-3-600 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 17, 2023

                            Lead Product(s) : TORL-3-600

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $158.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            TORL BioTherapeutics Launches with $158 Million Series B Financing to Advance Development of Novel Oncology Bi...

                            Details : The net funding will used to advance TORL-1-23, a first-in-class, clinical-stage ADC targeting Claudin 6, TORL-2-307, a clinical-stage ADC targeting Claudin 18.2 and other novel clinical and preclinical stage programs.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            April 13, 2023

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Goldman Sachs & Co

                            Deal Size : $158.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-2-307-MAB

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

                            Details : TORL-2-307-MAB is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 16, 2021

                            Lead Product(s) : TORL-2-307-MAB

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-2-307-ADC

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

                            Details : TORL-2-307-ADC is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 14, 2021

                            Lead Product(s) : TORL-2-307-ADC

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TORL BioTherapeutics

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First in Human Study of TORL-1-23 in Participants With Advanced Cancer

                            Details : TORL-1-23 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            November 02, 2021

                            Lead Product(s) : TORL-1-23

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Translational Research In Oncology

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth